The blockage of KCa 3.1 channel inhibited proliferation, migration and promoted apoptosis of human hepatocellular carcinoma cells

Journal of Cancer

Volumn 6, Issue 7, 2015, Pages 643-651

  Liu, Yu ^a   Zhao, Liang ^a   Ma, Wenya ^a   Cao, Xuefeng ^b   Chen, Hongyang ^a   Feng, Dan ^a   Liang, Jing ^a   Yin, Kun ^a   Jiang, Xiaofeng ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b CHENGDE MEDICAL COLLEGE   (China)

Author keywords

Apoptosis; Migration; P53; Proliferation; ROS; TRAM 34

Indexed keywords

1 [(2 CHLOROPHENYL)DIPHENYLMETHYL] 1H PYRAZOLE; INTERMEDIATE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; MESSENGER RNA; POTASSIUM CHANNEL KCA3.1; PROTEIN P53; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; 1 ETHYL 2 BENZIMIDAZOLINONE;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; DRUG MECHANISM; GENE SILENCING; HEPG2 CELL LINE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MIGRATION INHIBITION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; ANTINEOPLASTIC ACTIVITY; CELL CULTURE; CELL MIGRATION; CELL PROLIFERATION; IMMUNOFLUORESCENCE MICROSCOPY; TUNEL ASSAY; WESTERN BLOTTING;

EID: 84938378706     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.11913     Document Type: Article

References (25)

1. Pinyol R, Llovet JM. Hepatocellular carcinoma: Genome-scale metabolic models for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2014. doi:nrgastro.2014; doi:10.1038/nrgastro.2014.70.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55: 74-108.
3. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996; 334: 693-9. doi:10.1056/NEJM199603143341104.
4. Chalasani N, Said A, Ness R, Hoen H, Lumeng L. Screening for hepatocellular carcinoma in patients with cirrhosis in the United States: results of a national survey. Am J Gastroenterol. 1999; 94: 2224-9. doi:10.1111/j.1572-0241.1999.01297.x.
5. Toyama K, Wulff H, Chandy KG, Azam P, Raman G, Saito T, et al. The intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to atherogenesis in mice and humans. J Clin Invest. 2008; 118: 3025-37. doi:10.1172/JCI30836.
6. Neylon CB, Lang RJ, Fu Y, Bobik A, Reinhart PH. Molecular cloning and characterization of the intermediate-conductance Ca(2+)-activated K(+) channel in vascular smooth muscle: relationship between K(Ca) channel diversity and smooth muscle cell function. Circ Res. 1999; 85: e33-43.
7. Klein H, Garneau L, Trinh NT, Prive A, Dionne F, Goupil E, et al. Inhibition of the KCa3.1 channels by AMP-activated protein kinase in human airway epithelial cells. Am J Physiol Cell Physiol. 2009; 296: C285-95. doi:10.1152/ajpcell.00418.2008.
8. Chou CC, Lunn CA, Murgolo NJ. KCa3.1: target and marker for cancer, autoimmune disorder and vascular inflammation? Expert Rev Mol Diagn. 2008; 8: 179-87. doi:10.1586/14737159.8.2.179.
9. Tharp DL, Wamhoff BR, Wulff H, Raman G, Cheong A, Bowles DK. Local delivery of the KCa3.1 blocker, TRAM-34, prevents acute angioplasty-induced coronary smooth muscle phenotypic modulation and limits stenosis. Arterioscler Thromb Vasc Biol. 2008; 28: 1084-9. doi:10.1161/ATVBAHA.107.155796.
10. Grgic I, Kiss E, Kaistha BP, Busch C, Kloss M, Sautter J, et al. Renal fibrosis is attenuated by targeted disruption of KCa3.1 potassium channels. Proc Natl Acad Sci U S A. 2009; 106: 14518-23. doi:10.1073/pnas.0903458106.
11. Wang ZH, Shen B, Yao HL, Jia YC, Ren J, Feng YJ, et al. Blockage of intermediate-conductance-Ca(2+)-activated K(+) channels inhibits progression of human endometrial cancer. Oncogene. 2007; 26: 5107-14. doi:10.1038/sj.onc.1210308.
12. Bellomo G, Perotti M, Taddei F, Mirabelli F, Finardi G, Nicotera P, et al. Tumor necrosis factor alpha induces apoptosis in mammary adenocarcinoma cells by an increase in intranuclear free Ca2+ concentration and DNA fragmentation. Cancer Res. 1992; 52: 1342-6.
13. Chandra-Kuntal K, Lee J, Singh SV. Critical role for reactive oxygen species in apoptosis induction and cell migration inhibition by diallyl trisulfide, a cancer chemopreventive component of garlic. Breast Cancer Res Treat. 2013; 138: 69-79. doi:10.1007/s10549-013-2440-2.
14. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 1994; 9: 1799-805.
15. Bishayee K, Ghosh S, Mukherjee A, Sadhukhan R, Mondal J, Khuda-Bukhsh AR. Quercetin induces cytochrome-c release and ROS accumulation to promote apoptosis and arrest the cell cycle in G2/M, in cervical carcinoma: signal cascade and drug-DNA interaction. Cell Prolif. 2013; 46: 153-63. doi:10.1111/cpr.12017.
16. Nies AT, Konig J, Pfannschmidt M, Klar E, Hofmann WJ, Keppler D. Expression of the multidrug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma. Int J Cancer. 2001; 94: 492-9. doi:10.1002/ijc.1498 [pii].
17. Jager H, Dreker T, Buck A, Giehl K, Gress T, Grissmer S. Blockage of intermediate-conductance Ca2+-activated K+ channels inhibit human pancreatic cancer cell growth in vitro. Mol Pharmacol. 2004; 65: 630-8. doi:10.1124/mol.65.3.630.
18. Lallet-Daher H, Roudbaraki M, Bavencoffe A, Mariot P, Gackiere F, Bidaux G, et al. Intermediate-conductance Ca2+-activated K+ channels (IKCa1) regulate human prostate cancer cell proliferation through a close control of calcium entry. Oncogene. 2009; 28: 1792-806. doi:10.1038/onc.2009.25.
19. Hsu JL, Pan SL, Ho YF, Hwang TL, Kung FL, Guh JH. Costunolide induces apoptosis through nuclear calcium2+ overload and DNA damage response in human prostate cancer. J Urol. 2011; 185: 1967-74. doi:10.1016/j.juro.2010.12.091.
20. Kim KW, Choi CH, Kim TH, Kwon CH, Woo JS, Kim YK. Silibinin inhibits glioma cell proliferation via Ca2+/ROS/MAPK-dependent mechanism in vitro and glioma tumor growth in vivo. Neurochem Res. 2009; 34: 1479-90. doi:10.1007/s11064-009-9935-6.
21. Drygin D, O'Brien SE, Hannan RD, McArthur GA, Von Hoff DD. Targeting the nucleolus for cancer-specific activation of p53. Drug Discov Today. 2013. doi:10.1016/j.drudis.2013.08.012.
22. Yaguchi T, Nakano T, Gotoh A, Nishizaki T. Adenosine promotes GATA-2-regulated p53 gene transcription to induce HepG2 cell apoptosis. Cell Physiol Biochem. 2011; 28: 761-70. doi:10.1159/000335770.
23. Sipeki S, Bander E, Ways DK, Farago A. Activation of Erk1/Erk2 and transiently increased p53 levels together may account for p21 expression associated with phorbol ester-induced transient growth inhibition in HepG2 cells. Cell Signal. 2002; 14: 115-21.
24. Lee YS, Jin DQ, Kwon EJ, Park SH, Lee ES, Jeong TC, et al. Asiatic acid, a triterpene, induces apoptosis through intracellular Ca2+ release and enhanced expression of p53 in HepG2 human hepatoma cells. Cancer Lett. 2002; 186: 83-91.
25. Barlev NA, Liu L, Chehab NH, Mansfield K, Harris KG, Halazonetis TD, et al. Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol Cell. 2001; 8: 1243-54.